FindTrial
Sign In

Inhaled Long-Acting Muscarinic Antagonist

DRUG2 trials

Sponsors

Sanofi

Conditions

Chronic Obstructive Pulmonary Disease

Phase 3

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation
CompletedNCT03930732
SanofiChronic Obstructive Pulmonary Disease
Start: 2019-04-15End: 2023-05-02Updated: 2024-02-28
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
CompletedNCT04456673
SanofiChronic Obstructive Pulmonary Disease
Start: 2020-07-06End: 2024-05-27Updated: 2025-05-29

Related Papers

Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial.
2025-07-095 citations
Reduction of Exacerbations According to Type 2 Inflammatory Biomarkers With Dupilumab Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)
American Journal of Respiratory and Critical Care Medicine2025-05-01
Dupilumab Efficacy in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation Across Baseline Eosinophil Counts
American Journal of Respiratory and Critical Care Medicine2025-05-01
Type 2 Inflammatory Biomarkers and Lung Function Improvement in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Placebo Therapy
American Journal of Respiratory and Critical Care Medicine2025-05-01
Dupilumab Efficacy in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation With and Without Emphysema
American Journal of Respiratory and Critical Care Medicine2025-05-01
Impact of Dupilumab on Type 2 Inflammatory Biomarkers in Patients With Chronic Obstructive Pulmonary Disease (COPD)
American Journal of Respiratory and Critical Care Medicine2025-05-01
Dupilumab Improves Lung Function in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation: A Pooled Analysis from the Phase 3 NOTUS and BOREAS Trials
American Journal of Respiratory and Critical Care Medicine2025-05-01
Win Ratio Analysis of BOREAS and NOTUS: Faster Trials, Clearer Wins for Patients With Chronic Obstructive Pulmonary Disease With Type 2 Inflammation
American Journal of Respiratory and Critical Care Medicine2025-05-01
Impact of Dupilumab Treatment on Lung Function in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
American Journal of Respiratory and Critical Care Medicine2025-05-01
Dupilumab Efficacy in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation by Evaluating Respiratory Symptoms in COPD (E-RS:COPD) Breathlessness and St. George's Respiratory Questionnaire (SGRQ) Activity Scores
American Journal of Respiratory and Critical Care Medicine2025-05-01
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores
Respiratory Medicine2025-02-281 citations
Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS.
2025-01-317 citations
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
New England Journal of Medicine2024-05-20192 citations
S31 Efficacy of dupilumab in chronic obstructive pulmonary disease with type 2 inflammation by baseline blood eosinophil count
2023-11-011 citations
Late Breaking Abstract - Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils
2023-09-09
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
New England Journal of Medicine2023-05-21399 citations
Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies.
2023-03-312 citations